GlassScriptPhysician profile
Susan G Benesh
NPI 1174917710
$1,850.96
in general payments reported to CMS, 2019-2025
25 companies · $1,044 in 2025
The $1,044 reported for 2025 was more than what 85% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $238 · 2024: $569 · 2025: $1,044.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,851.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,850.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $360.35 | 2023-2025 | Repatha, Repatha |
| Novo Nordisk INC | $229.75 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $149.94 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $118.82 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $108.99 | 2024-2025 | Onpattro |
| Atricure, INC. | $100.89 | 2024-2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Boston Scientific Corporation | $89.06 | 2024 | Bodyguardian |
| Merck Sharp & Dohme LLC | $77.85 | 2024-2025 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $60.82 | 2024-2025 | Wainua, Lokelma, Farxiga |
| Esperion Therapeutics, INC. | $60.19 | 2024-2025 | Nexletol |
| Abiomed | $58.72 | 2024-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $57.91 | 2024-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $55.94 | 2025 | Lumryz |
| Janssen Pharmaceuticals, INC | $44.96 | 2023-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $44.85 | 2024-2025 | Camzyos, Eliquis |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $35.44 | 2023-2024 | |
| Corcept Therapeutics | $32.17 | 2025 | Korlym |
| Bridgebio Pharma, INC. | $27.21 | 2025 | Attruby |
| Actelion Pharmaceuticals US, INC. | $25.05 | 2025 | Uptravi, Opsynvi |
| Lexicon Pharmaceuticals, INC. | $24.21 | 2023 | Inpefa |
| Philips North America LLC | $21.94 | 2025 | Event |
| Lilly USA, LLC | $18.39 | 2025 | Zepbound, Mounjaro |
| Abbott Laboratories | $16.83 | 2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Cvrx, INC. | $16.77 | 2025 | Barostim Neo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.91 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Benesh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.